Metronidazole therapy in mice infected with tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 5, 1999, Pages 1285-1288

  Brooks, Jason V ^a   Furney, Synthia K ^a   Orme, Ian M ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; METRONIDAZOLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL GROWTH; BACTERIAL METABOLISM; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG POTENCY; FEMALE; GROWTH INHIBITION; INHALATIONAL DRUG ADMINISTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

EID: 0032930277     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.5.1285     Document Type: Article

References (24)

1. Chan, J., X. D. Fan, S. W. Hunter, P. J. Brennan, and B. R. Bloom. 1991. Lipoarabinomannan, a possible virulence factor involved in persistence of Mycobacterium tuberculosis within macrophages. Infect. Immun. 59:1755-1761.
2. Cooper, A. M., J. E. Callahan, M. Keen, J. T. Belisle, and I. M. Orme. 1997. Expression of memory immunity in the lung following re-exposure to Mycobacterium tuberculosis. Tubercle Lung Dis. 78:67-73.
3. Cooper, A. M., and I. M. Orme. Unpublished observations.
4. DeMaio, J., Y. Zhang, C. Ko, and W. R. Bishai. 1997. Mycobacterium tuberculosis sigF is part of a gene cluster with similarities to the Bacillus subtilis sigF and sigB operons. Tubercle Lung Dis. 78:3-12.
5. Desai, C. R., S. Heera, A. Patel, A. B. Babrekar, A. A. Mahashur, and S. R Kamat. 1989. Role of metronidazole in improving response and specific drug sensitivity in advanced pulmonary tuberculosis. J. Assoc. Physicians India 37:694-697.
6. Dhillon, J., J. M. Dickinson, K. Sole, and D. A. Mitchison. 1996 Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide. Antimicrob. Agents Chemother. 40: 552-555.
7. Edwards, D. I. 1977. The action of metronidazole on DNA. J. Antimicrob. Chemother. 3:43-48.
8. Knight, R. C., I. M. Skolimoowski, and D. I. Edwards. 1978. Effect of reduced metronidazole on DNA. Biochem. Pharmacol. 27:2089-2093.
9. Lau, A. H., N. P. Lam, S. C. Piscitelli, L. Wilkes, and L. H. Danzinger. 1992. Clinical pharmacokinetics of metronidazole and other nitroimidazole antiinfectives. Clin. Pharmacokinet. 23:328-364.
10. McCune, R. M., and R. Tompsett. 1956. Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. I. The persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy. J. Exp. Med. 104:737-762.
11. Orme, I. M. 1987. The kinetics of emergence and loss of mediator T lymphocytes acquired in response to infection with Mycobacterium tuberculosis. J. Immunol. 138:293-298.
12. Orme, I. M. 1988. Characteristics and specificity of acquired immunologic memory to Mycobacterium tuberculosis infection. J. Immunol. 140:3589-3593.
13. Orme, I. M., and D. N. McMurray. 1996. The immune response to tuberculosis in animals, p. 269-280. In W. N. Rom and S. Garay (ed.), Tuberculosis infections. Little, Brown, & Company, New York, N.Y.
14. Rhoades, E. R., and I. M. Orme. 1997. Susceptibility of a panel of virulent strains of Mycobacterium tuberculosis to reactive nitrogen intermediates. Infect. Immun. 65:1189-1195.
15. Rhoades, E. R., A. A. Frank, and I. M. Orme. 1997. Progression of pulmonary tuberculosis in mice aerogenically infected with virulent Mycobacterium tuberculosis. Tubercle Lung Dis. 78:57-66.
16. Russell, D. G., S. Sturgill-Koszycki, T. Vanheyningen, H. Collins, and U. E. Schaible. 1997. Why intracellular parasitism need not be a degrading experience for Mycobacterium. Phil. Trans. R. Soc. London 352:1303-1310.
17. Skinner, P. S., S. K. Furney, M. K. Jacobs, G. Klopman, J. J. Ellner, and I. M. Orme. 1994. A bone marrow derived murine macrophage model for evaluating efficacy of anti-myocobacterial drugs under relevant physiological conditions. Antimicrob. Agents Chemother. 38:2557-2563.
18. Stanford, J. L. 1987. Much's granules revisited. Tubercle. 68:241-242.
19. Wayne, L. G. 1976. Dynamics of submerged growth of Mycobacterium tuberculosis under aerobic and microaerophilic conditions. Am. Rev. Respir. Dis. 114:807-811.
20. Wayne, L. G. 1994. Dormancy of Mycobacterium tuberculosis and latency of disease. Eur. J. Clin. Microbiol. Infect. Dis. 13:908-914.
21. Wayne, L. G., and G. A. Diaz. 1967. Autolysis and secondary growth of Mycobacterium tuberculosis in submerged culture. J. Bacteriol. 93:1374-1381.
22. Wayne, L. G., and L. G. Hayes. 1996. An in vivo model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect. Immun. 64:2062-2069.
23. Wayne, L. G., and H. A. Sramek. 1994. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 38:2054-2058.
24. Wayne, L. G., and K.-Y. Lin. 1982. Glyoxylate metabolism and adaptation of Mycobacterium tuberculosis to survival under anaerobic conditions. Infect. Immun. 37:1042-1049.